Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
AgeNot listed
SponsorAlnylam Pharmaceuticals
About this trial
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
Eligibility criteria
Qualifiers
Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy
Disqualifiers
There are no exclusion criteria for participation in this program.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
10 Participants
are grouped into 1 trial groupLocations
7France
Clinical Trial Site Nantes France
Germany
Clinical Trial Site Münster Germany
Italy
Clinical Trial Site Pavia Italy
Netherlands
Clinical Trial Site Groningen Netherlands
Sponsors and collaborators
Alnylam Pharmaceuticals
Lead sponsor
Source ClinicalTrials.gov